FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023346093> ?p ?o ?g. }

• W2023346093 endingPage "940" @default.
• W2023346093 startingPage "936" @default.
• W2023346093 abstract "No AccessJournal of UrologyAdult urology1 Mar 2008The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminomais accompanied byEarly Orchiopexy Improves Subsequent Testicular Development and Spermatogenesis in the Experimental Cryptorchid Rat Model Stefan Hinz, Mark Schrader, Carsten Kempkensteffen, Roland Bares, Winfried Brenner, Susanne Krege, Christiane Franzius, Sabine Kliesch, Ruediger Heicappel, Kurt Miller, and Maike de Wit Stefan HinzStefan Hinz Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author , Mark SchraderMark Schrader Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author , Carsten KempkensteffenCarsten Kempkensteffen Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author , Roland BaresRoland Bares Department of Nuclear Medicine, University Hospital Tuebingen, Tuebingen, Germany More articles by this author , Winfried BrennerWinfried Brenner Department of Nuclear Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany More articles by this author , Susanne KregeSusanne Krege Department of Urology, University Hospital Essen, Essen, Germany More articles by this author , Christiane FranziusChristiane Franzius Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany More articles by this author , Sabine KlieschSabine Kliesch Department of Urology, University Hospital Muenster, Muenster, Germany More articles by this author , Ruediger HeicappelRuediger Heicappel Department of Urology, Hospital Uckermark, Schwedt, Germany More articles by this author , Kurt MillerKurt Miller Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author , and Maike de WitMaike de Wit Department of Medicine and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2007.10.054AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Treatment in patients with seminoma who have residual or recurrent masses following chemotherapy is still a matter of debate. Surgical resection is currently the most common recommendation for masses greater than 3 cm, resulting in overtreatment in up to 70% of those affected. We analyzed the accuracy of preoperative positron emission tomography for predicting viable tumor residuals in patients with seminoma. Materials and Methods: In a prospective, multicenter trial computerized tomography and FDG (2-(F-18)-fluoro-2-deoxy-D-glucose) positron emission tomography were performed before surgical resection for residual or recurrent masses in 20 patients who had undergone chemotherapy for stage IIb, IIc or III seminoma. Histopathological findings were directly correlated with positron emission tomography results. Results: Of the patients 18 presented with residual masses and 2 had recurrent masses following chemotherapy. Histopathological assessment revealed viable tumor in 3 patients and benign lesions in 17. All patients with viable tumor were identified correctly by positron emission tomography. No false-negative results were observed but 9 patients had false-positive positron emission tomography results. This resulted in a negative predictive value of 1 (95% CI 0.63–1) and a positive predictive value of 0.25 (95% CI 0.05–0.57) for FDG-positron emission tomography in our patient cohort. Conclusions: Our data indicate that FDG-positron emission tomography is capable of excluding viable disease in residual masses, even those exceeding 3 cm. Therefore, it may be considered an additional tool to improve patient counseling. However, the decision to perform surgical resection of the residual mass should not be based exclusively on a positive positron emission tomography image since false-positive results appear to be common. References 1 : Trends in the incidence of testicular germ cell tumors in the United States. Cancer2003; 97: 63. Google Scholar 2 : Management of post-chemotherapy residual masses in advanced seminoma. J Urol2002; 168: 1975. Link, Google Scholar 3 : Surgery for a post-chemotherapy residual mass in seminoma. J Urol1997; 157: 860. Link, Google Scholar 4 : Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?. J Urol2003; 169: 2126. Link, Google Scholar 5 : FDG-PET for clinical use: Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III,” 21 July and 19 September 2000. Eur J Nucl Med2001; 28: 1707. Google Scholar 6 : Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol1996; 14: 1637. Google Scholar 7 : 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol2004; 22: 1034. Google Scholar 8 : Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol1999; 17: 3457. Crossref, Medline, Google Scholar 9 : International germ cell consensus classification: a prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol1997; 15: 594. Google Scholar 10 : TNM Classification of Malignant Tumors. New York: John Wiley and Sons2002. Google Scholar 11 : Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer2002; 94: 2353. Google Scholar 12 : Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol1987; 138: 77. Link, Google Scholar 13 : Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role: MRC Testicular Tumour Working Party. Eur J Cancer1997; 33: 829. Google Scholar 14 : Management of stage II seminoma. J Clin Oncol1998; 16: 290. Google Scholar 15 : Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer2000; 83: 863. Google Scholar 16 : The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int2002; 89: 549. Google Scholar 17 : Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J2003; 33: 427. Google Scholar 18 : Cancer or inflammation?: A Holy Grail for nuclear medicine. J Nucl Med1994; 35: 1653. Google Scholar 19 : Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer1997; 33: 1234. Google Scholar 20 : Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med1994; 21: 297. Google Scholar 21 : Sarcoidosis and testicular carcinoma. Cancer1998; 83: 337. Google Scholar 22 : European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol2004; 15: 1377. Google Scholar 23 : Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874: EORTC GU Group. Br J Cancer1995; 71: 619. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology17 Jan 2008Early Orchiopexy Improves Subsequent Testicular Development and Spermatogenesis in the Experimental Cryptorchid Rat Model Volume 179Issue 3March 2008Page: 936-940 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordspositron-emission tomographyseminomalocaltesticular neoplasmsneoplasm recurrenceMetricsAuthor Information Stefan Hinz Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author Mark Schrader Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author Carsten Kempkensteffen Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author Roland Bares Department of Nuclear Medicine, University Hospital Tuebingen, Tuebingen, Germany More articles by this author Winfried Brenner Department of Nuclear Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany More articles by this author Susanne Krege Department of Urology, University Hospital Essen, Essen, Germany More articles by this author Christiane Franzius Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany More articles by this author Sabine Kliesch Department of Urology, University Hospital Muenster, Muenster, Germany More articles by this author Ruediger Heicappel Department of Urology, Hospital Uckermark, Schwedt, Germany More articles by this author Kurt Miller Department of Urology, Charité Campus Benjamin Franklin, Universitaetsmedizin Berlin, Berlin, Germany More articles by this author Maike de Wit Department of Medicine and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2023346093 created "2016-06-24" @default.
• W2023346093 creator A5000710774 @default.
• W2023346093 creator A5017015998 @default.
• W2023346093 creator A5017446958 @default.
• W2023346093 creator A5019298885 @default.
• W2023346093 creator A5026601540 @default.
• W2023346093 creator A5026847363 @default.
• W2023346093 creator A5048386880 @default.
• W2023346093 creator A5055275116 @default.
• W2023346093 creator A5067547650 @default.
• W2023346093 creator A5069332516 @default.
• W2023346093 creator A5083968227 @default.
• W2023346093 date "2008-03-01" @default.
• W2023346093 modified "2023-10-18" @default.
• W2023346093 title "The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma" @default.
• W2023346093 cites W142345876 @default.
• W2023346093 cites W1520056300 @default.
• W2023346093 cites W1588594211 @default.
• W2023346093 cites W1850721857 @default.
• W2023346093 cites W1895170789 @default.
• W2023346093 cites W2014451840 @default.
• W2023346093 cites W2025016076 @default.
• W2023346093 cites W2026167589 @default.
• W2023346093 cites W2039250483 @default.
• W2023346093 cites W2053107625 @default.
• W2023346093 cites W2061245689 @default.
• W2023346093 cites W2083162623 @default.
• W2023346093 cites W2086387061 @default.
• W2023346093 cites W2104375206 @default.
• W2023346093 cites W2109602377 @default.
• W2023346093 cites W2115709003 @default.
• W2023346093 cites W2129465453 @default.
• W2023346093 cites W2147188141 @default.
• W2023346093 cites W2299967106 @default.
• W2023346093 cites W2419393858 @default.
• W2023346093 cites W4382915988 @default.
• W2023346093 cites W44254208 @default.
• W2023346093 doi "https://doi.org/10.1016/j.juro.2007.10.054" @default.
• W2023346093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18207171" @default.
• W2023346093 hasPublicationYear "2008" @default.
• W2023346093 type Work @default.
• W2023346093 sameAs 2023346093 @default.
• W2023346093 citedByCount "77" @default.
• W2023346093 countsByYear W20233460932012 @default.
• W2023346093 countsByYear W20233460932013 @default.
• W2023346093 countsByYear W20233460932014 @default.
• W2023346093 countsByYear W20233460932015 @default.
• W2023346093 countsByYear W20233460932016 @default.
• W2023346093 countsByYear W20233460932017 @default.
• W2023346093 countsByYear W20233460932018 @default.
• W2023346093 countsByYear W20233460932019 @default.
• W2023346093 countsByYear W20233460932020 @default.
• W2023346093 countsByYear W20233460932021 @default.
• W2023346093 countsByYear W20233460932022 @default.
• W2023346093 countsByYear W20233460932023 @default.
• W2023346093 crossrefType "journal-article" @default.
• W2023346093 hasAuthorship W2023346093A5000710774 @default.
• W2023346093 hasAuthorship W2023346093A5017015998 @default.
• W2023346093 hasAuthorship W2023346093A5017446958 @default.
• W2023346093 hasAuthorship W2023346093A5019298885 @default.
• W2023346093 hasAuthorship W2023346093A5026601540 @default.
• W2023346093 hasAuthorship W2023346093A5026847363 @default.
• W2023346093 hasAuthorship W2023346093A5048386880 @default.
• W2023346093 hasAuthorship W2023346093A5055275116 @default.
• W2023346093 hasAuthorship W2023346093A5067547650 @default.
• W2023346093 hasAuthorship W2023346093A5069332516 @default.
• W2023346093 hasAuthorship W2023346093A5083968227 @default.
• W2023346093 hasConcept C11413529 @default.
• W2023346093 hasConcept C121332964 @default.
• W2023346093 hasConcept C126322002 @default.
• W2023346093 hasConcept C126838900 @default.
• W2023346093 hasConcept C146357865 @default.
• W2023346093 hasConcept C147120987 @default.
• W2023346093 hasConcept C151730666 @default.
• W2023346093 hasConcept C155512373 @default.
• W2023346093 hasConcept C185544564 @default.
• W2023346093 hasConcept C19527891 @default.
• W2023346093 hasConcept C202100949 @default.
• W2023346093 hasConcept C2775842073 @default.
• W2023346093 hasConcept C2776694085 @default.
• W2023346093 hasConcept C2778074268 @default.
• W2023346093 hasConcept C2989005 @default.
• W2023346093 hasConcept C41008148 @default.
• W2023346093 hasConcept C71924100 @default.
• W2023346093 hasConcept C86803240 @default.
• W2023346093 hasConceptScore W2023346093C11413529 @default.
• W2023346093 hasConceptScore W2023346093C121332964 @default.
• W2023346093 hasConceptScore W2023346093C126322002 @default.
• W2023346093 hasConceptScore W2023346093C126838900 @default.
• W2023346093 hasConceptScore W2023346093C146357865 @default.
• W2023346093 hasConceptScore W2023346093C147120987 @default.
• W2023346093 hasConceptScore W2023346093C151730666 @default.
• W2023346093 hasConceptScore W2023346093C155512373 @default.
• W2023346093 hasConceptScore W2023346093C185544564 @default.
• W2023346093 hasConceptScore W2023346093C19527891 @default.
• W2023346093 hasConceptScore W2023346093C202100949 @default.
• W2023346093 hasConceptScore W2023346093C2775842073 @default.

• next